Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Matrices
Reexamination Certificate
2011-06-28
2011-06-28
Maier, Leigh C (Department: 1623)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Matrices
C424S280100, C424S489000, C424S467000, C424S499000, C435S006120, C435S069100, C435S072000, C435S455000, C435S458000, C514S054000
Reexamination Certificate
active
07968123
ABSTRACT:
The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. Also disclosed are compounds having the formula:
REFERENCES:
patent: 4877778 (1989-10-01), Carpenter et al.
patent: 4887778 (1989-12-01), Soth et al.
patent: 5276088 (1994-01-01), Yoshinaga
patent: 5608015 (1997-03-01), Yoshinaga
patent: 5691316 (1997-11-01), Agrawal et al.
patent: 5698535 (1997-12-01), Geczy et al.
patent: 5728804 (1998-03-01), Sharma et al.
patent: 5855900 (1999-01-01), Nobuhiko
patent: 5880154 (1999-03-01), Boukrinskaia et al.
patent: 6048736 (2000-04-01), Kosak
patent: 6060597 (2000-05-01), Tobe et al.
patent: 6132734 (2000-10-01), Thomas et al.
patent: 6309633 (2001-10-01), Ekwuribe et al.
patent: 6420176 (2002-07-01), Lisziewicz et al.
patent: 6509323 (2003-01-01), Davis et al.
patent: 6667293 (2003-12-01), Zhao et al.
patent: 6740643 (2004-05-01), Wolff et al.
patent: 7132399 (2006-11-01), Hefeneider et al.
patent: 2001/0034333 (2001-10-01), Kosak
patent: 2001/0044412 (2001-11-01), Wolff et al.
patent: 2002/0107372 (2002-08-01), Hefeneider et al.
patent: 1 390 479 (1975-04-01), None
patent: 2 197 720 (1988-05-01), None
patent: 200913 (1990-04-01), None
patent: WO-94/28031 (1994-12-01), None
patent: WO-95/32739 (1995-12-01), None
patent: WO-96/09073 (1996-03-01), None
patent: WO-98/47536 (1998-10-01), None
patent: WO-99/47172 (1999-09-01), None
patent: WO-91/17300 (1999-11-01), None
patent: WO-00/01734 (2000-01-01), None
patent: WO-00/09073 (2000-02-01), None
patent: WO-00/33885 (2000-06-01), None
patent: WO-00/40962 (2000-07-01), None
patent: WO-00/75162 (2000-12-01), None
patent: WO-00/75164 (2000-12-01), None
patent: WO-01/37665 (2001-05-01), None
patent: WO-01/66601 (2001-09-01), None
patent: WO-02/049676 (2002-06-01), None
Szente, S. et al “Highly soluble cyclodextrin derivatives . . .” Adv. Drug Deliv. Rev. (1999) vol. 36, pp. 17-28.
Iser, J. et al “Chenodeoxycholic acid treatment of gallstones . . .” N. Engl. J. Med. (1975) vol. 293, No. 8, pp. 378-383 (abstract only).
Danysz, W. et al “Aminoadamantanes as NMDA receptor antagonists . . .” Neurosci. Biobehavioral Rev. (1997) vol. 21, No. 4, pp. 455-468.
Weickenmeier, M. et al “Cyclodextrin sidechain polyesters . . .” Macro mol. Rapid Commun. (1996) vol. 17, pp. 731-736.
Gosselet, N. et al “Association of hydrophobilcally modified . . .” Colloids and Surfaces A (1999) pp. 177-188.
Epa, E. et al “Downregulation of the p75 neurotrophin receptor . . .” Antisense Nucl. Acid Drug Dev. (2000) vol. 10, pp. 469-478.
Ikeda, T. et al “Supramolecular network formation through inclusion complexation . . .” Macromol. Rapid Commun. (2000) vol. 21, pp. 1257-1262.
“Adamantane,” in The Merck Index, 11th ed., Merck Research Laboratories, p. 24: No. 140 (1989).
“Amantadine,” in The Merck Index, 11th ed., Merck Research Laboratories, p. 60: No. 380 (1989).
Amiel et al., “Association Between Amphiphilic Poly(ethylene oxide) and β-Cyclodextrin Polymers: Aggregation and Phase Separation,” Advances in Colloid and Interface Science 79:105-122 (1999).
Amiel et al., “Associations Between Hydrophibically End-Capped Polyethylene Oxide and Water Soluble β Cyclodextrin Polymers,” Int. J. Polymer Analysis & Characterization 1:289-300 (1995).
Amiel et al., “New Associating Polymer Systems Involving Water Soluble β-Cyclodextrin Polymers,” Journal of Inclusion Phemomena and Molecular Recognition in Chemistry 25:61-67 (1996).
Boussif et al., “A Versatile Vector for Gene and Oligonucleotide Transfer into Cells in Culture and in vivo: Polyethyleninmine,” Proceedings of the National Academy of Sciences 92(16):7297-7301 (1995).
Breslow et al., “Cholesterol Recognition and Binding by Cyclodextrin Dimers,” J. Am. Chem. Soc. 118:8495-8496 (1996).
Cserhati, “Charge-Transfer Chromatographic Study of the Complex Formation of Some Anticancer Drugs with γ-Cyclodextrin,” Analytical Biochemistry 225:328-332 (1995).
Finsinger et al., “Protective Copolymers for Nonviral Gene Vectors: Synthesis, Vector Characterization and Application in Gene Delivery,” Gene Delivery 7:1183-1192 (2000).
Fisher, “A Versatile System for Receptor-Mediated Gene Delivery Permits Increased Entry of DNA into Target Cells, Enhanced Delivery to the Nucleus and Elevated Rates of Transgene Expression,” Gene Therapy 7:1337-1343 (2000).
Gonzalez et al., “New Class of Polymers for the Delivery of Macromolecular Therapeutics,” Bioconjugate Chem 10(6):1068-1074 (1999).
Husain et al., “Complexation of Doxorubicin with β- and γ-Cyclodextrins,” Applied Spectroscopy 46(4):652-658 (1992).
Hwang et al., “Effects of Structure of β-Cyclodextrin-Containing Polymers on Gene Delivery,” Bioconjugate Chem 12(2):280-290 (2001).
Ooya et al., “Synthesis and Characterization of an Oligopeptide-terminated Polyrotaxane as a Drug Carrier,” Polym. Adv. Technol. 11:642-651 (2000).
Pun et al., “Development of a Nonviral Gene Delivery Vehicle for Systemic Application,” Bioconjugate Chem. 13:630-639 (2002).
Sandier, “Interaction Between an Adamantane End-Capped Poly(ethylene oxide) and a β-Cyclodextrin Polymer,” Langmuir 16(4):1634-1642 (2000).
Tabushi et al., “Artificial Receptor Recognizing Hydrophobic Carbonyl Compounds,” Journal of Organic Chemistry 51(10):1918-1921 (1986).
Tojima et al., “Preparation of an α-Cyclodextrin-Linked Chitosan Derivative via Reductive Amination Strategy,” J. Polym. Sci., Part A: Polym. Chem. 36:1965-1968 (1998).
Torchilin et al., “TAT Peptide on the Surface of Liposomes Affords Their Efficient Intracellular Delivery Even at Low Temperature and in the Presence of ametabolic Inhibitors,” PNAS 98(15)8786-8791 (2001).
Uekama et al., “Cyclodextrin Drug Carrier Systems,” Chem. Rev. 98:2045-2076 (1998).
Zanta et al., “In Vitro Gene Delivery to Hepatocytes with Galactosylated Polyethylenimine,” Bioconjugate Chem. 8:839-844 (1997).
Zhang et al., “Enthalpic Domination of the Chelate Effect in Cyclodextrin Dimers,” J. Am. Chem. Soc. 115:9353-9354 (1993).
David et al, Synthesis of hydrophobically end-capped poly(ethyleneglycol)s with UV absorbing properties. Macromol. Rapid Commun. vol. 21, No. 14, pp. 990-993 (2000).
Du et al., “Steric Considerations in Supramolecular Incision of Modified β-Cyclodextrins with Triton X-100 and α-Bromonaphthalene,” Supramolecular Chem. 17:209-214 (2005).
Bellocq Nathalie C.
Cheng Jianjun
Davis Mark E.
Gonzalez Hector
Hwang Pun Suzie
Calando Pharmaceuticals, Inc.
California Institute of Technology
Maier Leigh C
Ropes & Gray LLP
LandOfFree
Complexing agents for compositions containing inclusion... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Complexing agents for compositions containing inclusion..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Complexing agents for compositions containing inclusion... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2676784